Recent advances in biologic therapy of asthma and the role in therapy of chronic rhinosinusitis

Devyani Lal, Rohit Divekar

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Great strides have been made in the last five years in understanding the pathology of chronic rhinosinusitis (CRS). CRS is now accepted to be the end-stage manifestation of inflammation resultant from various pathogenetic mechanisms. This has resulted in increasing recognition of distinct CRS endotypes. Such endotypes encompass a cluster of patients with similar pathogenic mechanisms that may have common therapeutic targets and responsiveness to interventions. The elucidation of mechanisms leading to the development of chronic upper (sino-nasal) airway inflammation has to some extent paralleled investigations of aberrant pathways operant in asthma. In this review, we focus on recent developments in understanding the innate immune pathways as well as adaptive (late) immune responses in CRS and asthma and their implication as potentially modifiable targets in CRS. Specific biologic therapy (that is, monoclonal antibodies targeting cytokines, cytokine receptors, or specific key molecules targeting inflammation) is an exciting proposition for the future of medical management of CRS. As of the writing of this article, the agents described are not approved for use in CRS; many have partial approval for use in asthma or are considered experimental.

Original languageEnglish (US)
Article number412
JournalF1000Research
Volume7
DOIs
StatePublished - Jan 1 2018

Fingerprint

Biological Therapy
Cytokine Receptors
Pathology
Asthma
Monoclonal Antibodies
Cytokines
Inflammation
Molecules
Adaptive Immunity
Nose
Therapeutics

Keywords

  • Biologics
  • Nasal polyp
  • Rhinosinusitis
  • Sinusitis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Recent advances in biologic therapy of asthma and the role in therapy of chronic rhinosinusitis. / Lal, Devyani; Divekar, Rohit.

In: F1000Research, Vol. 7, 412, 01.01.2018.

Research output: Contribution to journalReview article

@article{ba2c184acb9b44289ce84ce380a16d5c,
title = "Recent advances in biologic therapy of asthma and the role in therapy of chronic rhinosinusitis",
abstract = "Great strides have been made in the last five years in understanding the pathology of chronic rhinosinusitis (CRS). CRS is now accepted to be the end-stage manifestation of inflammation resultant from various pathogenetic mechanisms. This has resulted in increasing recognition of distinct CRS endotypes. Such endotypes encompass a cluster of patients with similar pathogenic mechanisms that may have common therapeutic targets and responsiveness to interventions. The elucidation of mechanisms leading to the development of chronic upper (sino-nasal) airway inflammation has to some extent paralleled investigations of aberrant pathways operant in asthma. In this review, we focus on recent developments in understanding the innate immune pathways as well as adaptive (late) immune responses in CRS and asthma and their implication as potentially modifiable targets in CRS. Specific biologic therapy (that is, monoclonal antibodies targeting cytokines, cytokine receptors, or specific key molecules targeting inflammation) is an exciting proposition for the future of medical management of CRS. As of the writing of this article, the agents described are not approved for use in CRS; many have partial approval for use in asthma or are considered experimental.",
keywords = "Biologics, Nasal polyp, Rhinosinusitis, Sinusitis",
author = "Devyani Lal and Rohit Divekar",
year = "2018",
month = "1",
day = "1",
doi = "10.12688/f1000research.13170.1",
language = "English (US)",
volume = "7",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Recent advances in biologic therapy of asthma and the role in therapy of chronic rhinosinusitis

AU - Lal, Devyani

AU - Divekar, Rohit

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Great strides have been made in the last five years in understanding the pathology of chronic rhinosinusitis (CRS). CRS is now accepted to be the end-stage manifestation of inflammation resultant from various pathogenetic mechanisms. This has resulted in increasing recognition of distinct CRS endotypes. Such endotypes encompass a cluster of patients with similar pathogenic mechanisms that may have common therapeutic targets and responsiveness to interventions. The elucidation of mechanisms leading to the development of chronic upper (sino-nasal) airway inflammation has to some extent paralleled investigations of aberrant pathways operant in asthma. In this review, we focus on recent developments in understanding the innate immune pathways as well as adaptive (late) immune responses in CRS and asthma and their implication as potentially modifiable targets in CRS. Specific biologic therapy (that is, monoclonal antibodies targeting cytokines, cytokine receptors, or specific key molecules targeting inflammation) is an exciting proposition for the future of medical management of CRS. As of the writing of this article, the agents described are not approved for use in CRS; many have partial approval for use in asthma or are considered experimental.

AB - Great strides have been made in the last five years in understanding the pathology of chronic rhinosinusitis (CRS). CRS is now accepted to be the end-stage manifestation of inflammation resultant from various pathogenetic mechanisms. This has resulted in increasing recognition of distinct CRS endotypes. Such endotypes encompass a cluster of patients with similar pathogenic mechanisms that may have common therapeutic targets and responsiveness to interventions. The elucidation of mechanisms leading to the development of chronic upper (sino-nasal) airway inflammation has to some extent paralleled investigations of aberrant pathways operant in asthma. In this review, we focus on recent developments in understanding the innate immune pathways as well as adaptive (late) immune responses in CRS and asthma and their implication as potentially modifiable targets in CRS. Specific biologic therapy (that is, monoclonal antibodies targeting cytokines, cytokine receptors, or specific key molecules targeting inflammation) is an exciting proposition for the future of medical management of CRS. As of the writing of this article, the agents described are not approved for use in CRS; many have partial approval for use in asthma or are considered experimental.

KW - Biologics

KW - Nasal polyp

KW - Rhinosinusitis

KW - Sinusitis

UR - http://www.scopus.com/inward/record.url?scp=85045020396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045020396&partnerID=8YFLogxK

U2 - 10.12688/f1000research.13170.1

DO - 10.12688/f1000research.13170.1

M3 - Review article

AN - SCOPUS:85045020396

VL - 7

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 412

ER -